Literature DB >> 9419191

Human herpesvirus 8 detection in nasal secretions and saliva.

D J Blackbourn1, E T Lennette, J Ambroziak, D V Mourich, J A Levy.   

Abstract

The presence of human herpesvirus 8 (HHV-8) was determined by polymerase chain reaction (PCR) in nasal secretions and saliva from 14 HHV-8-seropositive persons, including 8 Kaposi's sarcoma patients: 7 were human immunodeficiency virus type 1-infected, 6 of whom were asymptomatic. HHV-8 was detected in one or both body fluids in 8 (57%) of 14 subjects. Parallel PCR testing revealed the concomitant presence of cytomegalovirus, Epstein-Barr virus, and HHV-6 in various combinations in these body fluids. These data indicate frequent shedding of multiple herpesviruses in nasal secretions and saliva, particularly in Kaposi's sarcoma patients. Both body fluids are therefore potential sources HHV-8 by nonsexual transmission.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9419191     DOI: 10.1086/517356

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Comparison of serologic assays and PCR for diagnosis of human herpesvirus 8 infection.

Authors:  T J Spira; L Lam; S C Dollard; Y X Meng; C P Pau; J B Black; D Burns; B Cooper; M Hamid; J Huong; K Kite-Powell; P E Pellett
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Transcription pattern of human herpesvirus 8 open reading frame K3 in primary effusion lymphoma and Kaposi's sarcoma.

Authors:  P Rimessi; A Bonaccorsi; M Stürzl; M Fabris; E Brocca-Cofano; A Caputo; G Melucci-Vigo; M Falchi; A Cafaro; E Cassai; B Ensoli; P Monini
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 3.  Salivary biomarkers: toward future clinical and diagnostic utilities.

Authors:  Janice M Yoshizawa; Christopher A Schafer; Jason J Schafer; James J Farrell; Bruce J Paster; David T W Wong
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

4.  Risk Factors for Kaposi's Sarcoma-Associated Herpesvirus DNA in Blood and in Saliva in Rural Uganda.

Authors:  Angela Nalwoga; Marjorie Nakibuule; Vickie Marshall; Wendell Miley; Nazzarena Labo; Stephen Cose; Denise Whitby; Robert Newton
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

5.  Kaposi's sarcoma associated with previous human herpesvirus 8 infection in kidney transplant recipients.

Authors:  P Cattani; M Capuano; R Graffeo; R Ricci; F Cerimele; D Cerimele; G Nanni; G Fadda
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

6.  HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study.

Authors:  C Casper; D Carrell; K G Miller; F D Judson; A S Meier; J S Pauk; R A Morrow; L Corey; A Wald; C Celum
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

7.  High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy.

Authors:  Craig S Miller; Joseph R Berger; Yunanan Mootoor; Sergei A Avdiushko; Hua Zhu; Richard J Kryscio
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

8.  Comparison of serologic assays for detection of antibodies against human herpesvirus 8.

Authors:  J L Corchero; E C Mar; T J Spira; P E Pellett; N Inoue
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

9.  Fifty percent tissue culture infective dose assay for determining the titer of infectious human herpesvirus 8.

Authors:  Sagar V Nadgir; Heather R Hensler; Emilee R Knowlton; Charles R Rinaldo; Giovanna Rappocciolo; Frank J Jenkins
Journal:  J Clin Microbiol       Date:  2013-04-03       Impact factor: 5.948

Review 10.  Reflections on the interpretation of heterogeneity and strain differences based on very limited PCR sequence data from Kaposi's sarcoma-associated herpesvirus genomes.

Authors:  Jian-Chao Zong; Ravit Arav-Boger; Donald J Alcendor; Gary S Hayward
Journal:  J Clin Virol       Date:  2007-08-14       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.